SynthesisScientific reports2021
Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis.
Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk.International journal of molecular sciences · 2022Pooled it
- Lower lipoprotein(a) levels in patients with acute lacunar infarction.IBRO neuroscience reports · 2026Article
- Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives.Biomedicines · 2026Review
- Shared proteomic landscape between arteriosclerosis and cardiovascular endpoints: a Mendelian randomization and observational study integrating AlphaFold3 for structural prediction.Cardiovascular research · 2026Observational
- Factors Influencing Anxiety and Depression Symptoms in Patients With Acute Ischaemic Stroke and the Development and Validation of a Risk Prediction Model.Actas espanolas de psiquiatria · 2026Article
- Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.Journal of lipid and atherosclerosis · 2026Review
- Lipoprotein(a) and large artery atherosclerosis: results from the BIOSIGNAL study.Lipids in health and disease · 2026Observational
- Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort.Advances in lipoprotein(a) research · 2026Article
- Influence of Elevated Serum Lipoprotein(a) on Carotid Artery Plaque Ulceration in Patients Considered for Carotid Revascularization.Journal of atherosclerosis and thrombosis · 2026Article
- Demographics of lipoprotein(a) and stroke: The UK biobank.American journal of preventive cardiology · 2025Article
- Commentary on: Lipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Article
- The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank.American journal of preventive cardiology · 2025Article
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- Lipoprotein-a and white matter abnormalities: predicting small vessel disease in young patients with ischemic cerebrovascular events.Journal of neurology · 2025Article
- Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review.Journal of lipid and atherosclerosis · 2025Review
- Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.Journal of clinical medicine · 2025Review
- Article
- Lipoproteins predicting coronary lesion complexity in premature coronary artery disease: a supervised machine learning approach.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of lipoprotein-A [Lp (a)] as a risk factor for stroke is less well documented than for coronary heart disease. Hence, we conducted a systematic review and meta-analysis for the published observational studies in order to investigate the association of Lp (a) levels with the risk of stroke and its subtypes. In our meta-analysis, 41 studies involving 7874 ischemic stroke (IS) patients and 32,138 controls; 13 studies for the IS subtypes based on TOAST classification and 7 studies with 871 Intracerebral hemorrhage (ICH) cases and 2865 control subjects were included. A significant association between increased levels of Lp (a) and risk of IS as compared to control subjects was observed (standardized mean difference (SMD) 0.76; 95% confidence interval (CIs) 0.53-0.99). Lp (a) levels were also found to be significantly associated with the risk of large artery atherosclerosis (LAA) subtype of IS (SMD 0.68; 95% CI 0.01-1.34) as well as significantly associated with the risk of ICH (SMD 0.65; 95% CI 0.13-1.17) as compared to controls. Increased Lp (a) levels could be considered as a predictive marker for identifying individuals who are at risk of developing IS, LAA and ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.